OBLN vs. NVRO, INFU, TLSI, PDEX, SGHT, SRTS, TELA, LNSR, MGRM, and GUTS
Should you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Nevro (NVRO), InfuSystem (INFU), TriSalus Life Sciences (TLSI), Pro-Dex (PDEX), Sight Sciences (SGHT), Sensus Healthcare (SRTS), TELA Bio (TELA), LENSAR (LNSR), Monogram Orthopaedics (MGRM), and Fractyl Health (GUTS). These companies are all part of the "medical" sector.
Obalon Therapeutics vs.
Nevro (NYSE:NVRO) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership.
Nevro received 257 more outperform votes than Obalon Therapeutics when rated by MarketBeat users. Likewise, 63.11% of users gave Nevro an outperform vote while only 47.77% of users gave Obalon Therapeutics an outperform vote.
Nevro has a net margin of -16.54% compared to Obalon Therapeutics' net margin of -776.76%. Nevro's return on equity of -23.52% beat Obalon Therapeutics' return on equity.
Nevro has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, meaning that its share price is 223% less volatile than the S&P 500.
Nevro currently has a consensus price target of $6.30, indicating a potential upside of 34.76%. Given Nevro's stronger consensus rating and higher possible upside, research analysts clearly believe Nevro is more favorable than Obalon Therapeutics.
In the previous week, Nevro had 4 more articles in the media than Obalon Therapeutics. MarketBeat recorded 4 mentions for Nevro and 0 mentions for Obalon Therapeutics. Nevro's average media sentiment score of 0.11 beat Obalon Therapeutics' score of 0.00 indicating that Nevro is being referred to more favorably in the media.
95.5% of Nevro shares are owned by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are owned by institutional investors. 3.2% of Nevro shares are owned by company insiders. Comparatively, 8.1% of Obalon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Obalon Therapeutics has lower revenue, but higher earnings than Nevro.
Summary
Nevro beats Obalon Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Obalon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Obalon Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OBLN) was last updated on 1/22/2025 by MarketBeat.com Staff
Free OBLN Stock Alerts